Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 29;17:17562864241239740. doi: 10.1177/17562864241239740

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2024

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Frequencies of DMTs used across subsequent switches. Colored bars show the frequencies of DMTs used among treatment-switching PwMS (N = 1361), stratified by the sequence of DMT switches (from the first to the sixth DMT, respectively). Across the subsequent DMT switches, a decrease in the use of glatiramer acetate and DMF/DRF was observed, while the treatment with alemtuzumab, anti-CD20 MAB, cladribine, and teriflunomide increased.

*Market removal in March 2018.

Anti-CD20 MAB, anti-CD 20 monoclonal antibodies: ocrelizumab/ofatumumab/rituximab; DMF, dimethyl fumarate; DMT, disease-modifying therapy; DRF, diroximel fumarate; N, number of patients; PwMS, people with multiple sclerosis; S1P RM, sphingosine-1-phosphate receptor modulators: fingolimod/ozanimod/ponesimod/siponimod.